October 11, 2023 07:15 AM EDT
R&D

No­vo stops late-stage kid­ney tri­al for semaglu­tide ear­ly for ef­fi­ca­cy, da­ta com­ing in 2024

Katherine Lewin

News Reporter

No­vo Nordisk is stop­ping a Phase II­Ib kid­ney-fo­cused tri­al for its GLP-1 drug semaglu­tide ear­ly for ef­fi­ca­cy, the com­pa­ny an­nounced Tues­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

A service from the Financial Times